HOXA11 and cancer: The probability of surviving longer was observed with unmethylated HOXA11 promoter in cancer tissues (71.2 months (95% CI 57–85.3) vs. 44.3 months (95% CI 34.8–53.9) in methylated cases, log rank = 0.008) (Figure 1).